{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:12:00Z","timestamp":1791994320814,"version":"4.4.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"AMGEN","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone is the third most frequent metastatic site, and bone metastases (BM) are responsible for severe skeletal complications requiring dedicated care. There is no recent BM epidemiology data. This study aimed to describe incident BM patients in France between 2009 and 2018. We accessed the general sample of beneficiaries from the French health insurance reimbursement database. The algorithm identified new adult BM patients through the BM hospitalization code or through codes reflecting the onset of a skeletal-related event (SRE): severe bone pain, pathologic fracture, spinal compression, or hypercalcemia, in patients with a diagnosis of cancer. Patients with primary sarcoma or with prevalent BM during the 3\u00a0yr preceding the inclusion date were excluded. A total of 6663 new BM patients over 10\u00a0yr, corresponding to 775\u2009573 patients in the whole French population, were identified. The trend analysis of the overall crude rate of incident patients found a significant increase over the 2009-2018 period (average annual percent change of 8.6%, 95% CI [7.5; 9.7]). The most frequent primary cancer sites were breast (15.8%), prostate (13.4%), lung (12.6%), and digestive organs (10.6%). The median [IQR] follow-up was 1.3\u00a0yr [0.3-3.4] mainly interrupted by death (63.5%). Among BM patients, 4737 with SRE at inclusion or over the follow-up were identified. Over the period following the onset of an SRE, 66.4% received an opioid medication and 39.6% a nonsteroidal anti-inflammatory drug. Despite advances in oncology, BM concern a high number of patients. The burden of SRE is significant and preoccupant. Specific strategies to face this issue are urgent.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf081","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:55:54Z","timestamp":1746518154000},"source":"Crossref","is-referenced-by-count":10,"title":["Epidemiology of bone metastasis in France between 2009 and 2018"],"prefix":"10.1093","volume":"9","author":[{"given":"Clarisse","family":"Marchal","sequence":"first","affiliation":[{"name":"Pharmaco-Epid\u00e9miologie Lyon (PELyon) , Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[{"name":"Pharmaco-Epid\u00e9miologie Lyon (PELyon) , Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[{"name":"Amgen France , Boulogne-Billancourt F-92100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Amgen France , Boulogne-Billancourt F-92100 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Walter","sequence":"additional","affiliation":[{"name":"Pharmaco-Epid\u00e9miologie Lyon (PELyon) , Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bosco-Levy","sequence":"additional","affiliation":[{"name":"Bordeaux PharmacoEpi, INSERM CIC-P 1401, Universit\u00e9 de Bordeaux , Bordeaux F-33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut du Thorax, Institut Curie, Paris, and Paris Saclay, UVSQ , Versailles F-78000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Bouvard","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU Angers , Angers F-49933 ,","place":["France"]},{"name":"Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, Oniris, INSERM, M\u00e9decine R\u00e9g\u00e9n\u00e9ratrice et Squelette, RMeS, UMR 1229 , Angers F-49000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille B","family":"Confavreux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Claude Bernard Lyon 1, Universit\u00e9 de Lyon , Lyon F-69100 ,","place":["France"]},{"name":"D\u00e9partement de Rhumatologie, Centre Expert des M\u00e9tastases Osseuses (CEMOS), H\u00f4pital Lyon Sud, Institut de Canc\u00e9rologie des Hospices Civils de Lyon , Pierre-B\u00e9nite F-69495 ,","place":["France"]},{"name":"INSERM UMR1033 \u2013 LYOS, Universit\u00e9 de Lyon , Lyon F-69003 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"3","key":"2025072107262207000_ref1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol Rev"},{"issue":"11","key":"2025072107262207000_ref2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/fon.11.112","article-title":"Mechanisms of cancer cell metastasis to the bone: a multistep process","volume":"7","author":"Patel","year":"2011","journal-title":"Future Oncol"},{"issue":"4","key":"2025072107262207000_ref3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer. Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"issue":"2","key":"2025072107262207000_ref4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jbspin.2018.03.005","article-title":"Bone metastases from lung cancer: a paradigm for multidisciplinary onco-rheumatology management","volume":"86","author":"Confavreux","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2025072107262207000_ref5","volume-title":"Guidelines on Bone Metastases: 2024 Update","author":"Confavreux","year":"2024"},{"key":"2025072107262207000_ref6","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"issue":"20","key":"2025072107262207000_ref7","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025072107262207000_ref8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF00266372","article-title":"Metastatic bone disease from occult carcinoma: a profile","volume":"13","author":"Nottebaert","year":"1989","journal-title":"Int Orthop"},{"issue":"2","key":"2025072107262207000_ref9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2025072107262207000_ref10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2025072107262207000_ref11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","article-title":"Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer","volume":"26","author":"Yong","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"2025072107262207000_ref12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.bulcan.2021.08.006","article-title":"Opioid prescriptions in bone metastatic cancer patients: a cross sectional nationwide pharmacoepidemiological study","volume":"108","author":"Tarot","year":"2021","journal-title":"Bull Cancer"},{"issue":"22","key":"2025072107262207000_ref13","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.3390\/cancers13225711","article-title":"Fracture risk evaluation of bone metastases: a burning issue","volume":"13","author":"Confavreux","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025072107262207000_ref14","doi-asserted-by":"publisher","first-page":"106192","DOI":"10.1016\/j.clinbiomech.2024.106192","article-title":"The influence of femoral lytic tumors segmentation on autonomous finite element analysis","volume":"112","author":"Rachmil","year":"2024","journal-title":"Clin Biomech (Bristol)"},{"issue":"8","key":"2025072107262207000_ref15","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.arth.2018.02.096","article-title":"Total hip arthroplasty for periacetabular metastatic disease. An original technique of reconstruction according to the Harrington classification","volume":"33","author":"Wegrzyn","year":"2018","journal-title":"J Arthroplast"},{"issue":"3","key":"2025072107262207000_ref16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jvir.2022.12.011","article-title":"Percutaneous spindle osteosynthesis reinforced by cementoplasty on a pathological fracture of the distal clavicle","volume":"34","author":"Stacoffe","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"2025072107262207000_ref17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1754-9485.13587","article-title":"Interventional management of malignant bone tumours","volume":"67","author":"Cazzato","year":"2023","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"2025072107262207000_ref18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025072107262207000_ref19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bonekey.2014.75","article-title":"Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC)","volume":"3","author":"Confavreux","year":"2014","journal-title":"Bonekey Rep"},{"issue":"18","key":"2025072107262207000_ref20","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2025072107262207000_ref21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.4103\/jcrt.JCRT_824_17","article-title":"The features and prognostic impact of extracranial metastases in patients with epidermal growth factor receptor-mutant lung adenocarcinoma","volume":"14","author":"Bi","year":"2018","journal-title":"J Cancer Res Ther"},{"issue":"5","key":"2025072107262207000_ref22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10585-014-9648-3","article-title":"Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis","volume":"31","author":"Fujimoto","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"2025072107262207000_ref23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.05.006","article-title":"Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer","volume":"121","author":"Kuijpers","year":"2018","journal-title":"Lung Cancer"},{"key":"2025072107262207000_ref24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.bone.2018.01.004","article-title":"Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers","volume":"108","author":"Chambard","year":"2018","journal-title":"Bone"},{"issue":"2","key":"2025072107262207000_ref25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10198-020-01247-z","article-title":"Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are na\u00efve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events","volume":"22","author":"Hardtstock","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"3","key":"2025072107262207000_ref26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/03007995.2018.1532884","article-title":"Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population","volume":"35","author":"Bhowmik","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"2025072107262207000_ref27","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1007\/s00520-020-05357-5","article-title":"Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany","volume":"28","author":"Diel","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025072107262207000_ref28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR)","volume":"252","author":"Authors\/Task Force Members","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"2025072107262207000_ref29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2025072107262207000_ref30","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2025072107262207000_ref31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00018-021-04079-z","article-title":"An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis","volume":"79","author":"Zhang","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"2025072107262207000_ref32","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1097\/01.ASN.0000145894.57533.C4","article-title":"Vascular calcification mechanisms","volume":"15","author":"Giachelli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025072107262207000_ref33","volume-title":"Caisse Nationale de l'Assurance Maladie (CNAM). M\u00e9thodologie m\u00e9dicale de la Cartographie Des Pathologies et Des d\u00e9penses","year":"2023"},{"issue":"4","key":"2025072107262207000_ref34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","article-title":"Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event","volume":"34","author":"Ye","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025072107262207000_ref35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025072107262207000_ref36","doi-asserted-by":"publisher","first-page":"100505","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"2025072107262207000_ref37","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf055","article-title":"PD-1 blockade regulates skeletal remodeling in a sex- and age-dependent manner","volume":"3","author":"Joseph","year":"2025","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf081\/63071025\/ziaf081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf081\/63071025\/ziaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf081\/63071025\/ziaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:26:31Z","timestamp":1753097191000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf081\/8125939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf081","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,6]]},"article-number":"ziaf081"}}